Earnings Releases·Oct 26, 2026, 8:11 AM ET

Medifast — Third Quarter 2026 Earnings Summary

Revenue declined 19.4% year-over-year to $72.0 million, while GAAP net loss widened to $17.5 million ($1.57/share) from $2.3 million ($0.21/share) in the prior year; non-GAAP adjusted net loss was $2.1 million ($0.19/share).
The company reported a $13.8 million Catalyst Restructuring charge within SG&A, which increased total expenses 4.8% to $69.4 million, though non-GAAP adjusted SG&A fell 16.0% to $55.6 million.
Active earning coaches decreased 47.7% to 10,200 due to GLP-1 competition and market pressures, though revenue per coach rose 54.1% to $7,064; the number of coaches is expected to continue declining through year-end 2026.
Full-year 2026 revenue guidance is set at $280 million to $300 million with a GAAP loss per share of $1.80 to $2.05, while Q4 2026 revenue is projected between $55 million and $75 million.
Management confirmed the completion of the Catalyst restructuring and the market launch of the Trilivy™ system and new compensation plan, expressing confidence in achieving Q4 profitability.